The current standard-of-care for UC involves a treat-to-target approach, for which patients are regularly assessed to ensure that they are meeting disease control criteria. 2,8 Colonoscopy is a key component of this approach because it helps determine the extent and severity of UC, and helps guide the treatment strategy to achieve remission. 1,3,[8][9][10] For instance, Japanese guidelines 1,3 and other recommendations 9,11,12 state that colonoscopy should be regularly used to assess treatment response and improve disease management in patients with UC. Available treatments for UC consist of 5-aminosalicylic acid (5-ASA), immunomodulators, steroids, tofacitinib, and biologic therapies including vedolizumab, ustekinumab, and anti-tumor necrosis